The purpose of these FOAs is to encourage small businesses to develop technologies and approaches (i.e., novel ways to use new or existing technologies) that will enable researchers to better understand and manipulate the dynamic structure and/or function of brain localized G-protein coupled receptors (GPCRs) and/or potentially identify novel selective and specific agonists, antagonists, or allosteric modulators for these receptor subtypes, with a focus on mental health function or dysfunction. Technologies and approaches aimed at either well characterized receptor subtypes or understudied/orphan receptors would be of potential interest to NIMH. Clinical trials are not permitted for either opportunity.
- R41/R42 FOA
Amount: Please use total costs. If over $225,000 for Phase I and over $1,500,000 for Phase II (in all years) contact the OER SBIR/STTR Office about pursuing an SBA award cap waiver request
- R43/R44 FOA
Amount: Budgets of up to total $450,000 per year total cost for Phase I awards and $750,000 per year total cost for Phase II awards, and $1,000,000 per year total cost for phase IIB may be requested. Budgets of up to total $450,000 per year total cost for Phase I awards and $750,000 per year total cost for Phase II awards, and $1,000,000 per year total cost for phase IIB may be requested. Phase IIB budgets must be submitted in accordance with participating IC-specific budget limitations described in the current SBIR/STTR Program Descriptions and Research Topics of the NIH, CDC and FDA.
Application Deadline(s) (for both opportunities): Standard Dates through 9/6/21